April 1, 2016 — Pyrexar Medical announced a new distribution partnership with Clinitech Co. Ltd., bringing Pyrexar’s hyperthermia technologies into Cuba, the West Indies, Panama and Venezuela.
Cancer deaths are high in Cuba at 138 per 100,000, according to World Life Expectancy.com, an organization that tracks death causality throughout the world. Cuba cancer stats rank 31 in the world, slightly lower than the United Kingdom, and several points higher than the United States. According to a study in 2001-2003 by the National Cancer Registry, lung, prostate, throat and colon cancers had high incidence in men, while breast, cervix, lung and colon cancers were the most prevalent in women.
Clinitech will be providing sales and service for the Pyrexar family of superficial, interstitial and deep regional hyperthermia devices. Leading their team is Ross University School of Medicine Oncology Professor Kamal Malaker, M.D., Ph.D., who has successfully used hyperthermia technology in the treatment of cancer. “We are excited to bring this relatively under-explored, under-utilized, well-proven, life-saving technology to the region.” said Wazir Mohammed, Clinitech’s president.
The distribution territory includes: Antigua, Aruba, Bahamas, Barbados, Belize, Bermuda, Bonaire, British Virgin Islands, Cayman Islands, Cuba, Curacao, Dominica, Dominican Republic, Grenada, Guyana, Haiti, Jamaica, Montserrat, Panama, Puerto Rico, Saba, St. Ecstasies, St Kitts & Nevis, St. Lucia, St. Maarten, St. Vincent. Suriname, Trinidad and Tobago, Turks and Caicos, U.S. Virgin Islands (St. Thomas, St. Croix and St John) and Venezuela.
For more information: www.pyrexar.com
May 14, 2024 
